Dual GIP/GLP-1 agonist · LY3298176
A 39-amino-acid acylated peptide with dual activity at GIP and GLP-1 receptors. The most-cited dual incretin reference compound in current metabolic-research literature.
Research use only. Offer price applies to the 90mg size while this week's offer runs.
| Compound | Tirzepatide |
| Research category | Metabolic Research |
| Available sizes | 10mg, 20mg, 30mg, 40mg, 60mg, 90mg |
| Pricing | From £55 |
| Format | Lyophilised powder in sealed vial & pre-reconstituted pen |
| Purity | >99% by HPLC (Janoshik Analytical, batch-verified) |
| Intended use | In-vitro laboratory research only. Not for human consumption. |
Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.
| Compound class | Synthetic 39-amino-acid dual GIP / GLP-1 receptor agonist peptide |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.5 g/mol |
| CAS Registry Number | 2023788-19-2 |
| PubChem CID | 156588324 |
| Number of residues | 39 |
| Amino acid sequence | YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPS-NH2 (X = α-aminoisobutyric acid) |
| Receptor / mechanism | Dual agonist: GIP receptor (high affinity) + GLP-1 receptor (high affinity). |
| Reported half-life | Reported ~120 hours in primate models in the published literature. |
| Solubility | Lyophilised powder reconstitutes in bacteriostatic water for laboratory use. |
| Storage (lyophilised) | Stable at 2–8 °C in lyophilised form for 24+ months. |
| Storage (reconstituted) | Reconstituted: store at 2–8 °C, use within 28 days. |
| Clinical / regulatory status | Approved by FDA (2022) for type-2 diabetes / obesity research applications. |
Tirzepatide is a synthetic 39-amino-acid peptide characterised in the literature as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Supplied as lyophilised powder for in-vitro research use only.
The above describes how this compound is characterised in the published peer-reviewed literature. It is not a claim about effects in humans.
Tirzepatide is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.
Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration.
| State | Temperature | Shelf life |
|---|---|---|
| Lyophilised | 2–8 °C or −20 °C | Up to 24 months |
| Reconstituted | 2–8 °C | 4–6 weeks typical |
Every batch of Tirzepatide we supply is independently HPLC-verified by Janoshik Analytical. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.
Latest Janoshik report for Tirzepatide 10mg · task #231386 · analysed 25 Sep 2026
This report is for the batch, not the size. Janoshik’s HPLC test measures what the compound is and how pure it is, and its quantification confirms the amount in the vial tested. Every size of Tirzepatide is filled from the same tested batch, so this 10mg report covers 20mg, 30mg, 40mg, 60mg and 90mg as well. The report supplied with your order carries a verification key you can check on Janoshik’s own site.
| Purity | 99.568% |
| Measured content | 10.96 mg |
| Batch | L77Tirz2612 |
| Verification key | ZY5F38T7YXV3 |
Researchers working with Tirzepatide often work alongside the following compounds in the preclinical literature:
References are independent peer-reviewed sources. Lab77 Peptides is not affiliated with these publications.